申请人:Tris Pharma Inc.
公开号:US11241411B2
公开(公告)日:2022-02-08
A modified release benzonatate solid tablet or capsule is described which comprises a benzonatate adsorbate in a matrix with a sufficient amount of one or more pharmaceutically acceptable modified release pH-independent, substances to provide a modified release profile to the benzonatate, wherein there is substantially no benzonatate release from the tablet or capsule in the buccal cavity and no more than about 25% release of the benzonatate within 1 hour as determined in an in vitro dissolution assay.
本文描述了一种改良释放型苯骈那酯固体片剂或胶囊,它包括吸附在基质中的苯骈那酯,基质中含有足量的一种或多种药学上可接受的改良释放型 pH 值无关物质,以提供改良的苯骈那酯释放曲线,根据体外溶出度测定,片剂或胶囊在口腔中基本上没有苯骈那酯释放,1 小时内苯骈那酯释放量不超过约 25%。